BA-102 (nNOS Inhibitor)
Autism Spectrum Disorder / Phelan-McDermid Syndrome
PreclinicalProof of Concept
Key Facts
Indication
Autism Spectrum Disorder / Phelan-McDermid Syndrome
Phase
Preclinical
Status
Proof of Concept
Company
About Beyond Air
Beyond Air's mission is to disrupt the standard of care for inhaled nitric oxide therapy with its proprietary LungFit platform, which generates NO on-demand from ambient air. The company has achieved FDA approval for its LungFit PH system for neonatal hypoxic respiratory failure and is advancing a pipeline exploring high-concentration NO for viral pneumonia, chronic lung infections, and even oncology. Its strategy hinges on expanding the therapeutic applications of NO while leveraging a cost-effective, 'green' delivery technology to capture market share across hospital and home settings.
View full company profile